In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 14, 2010, Pages 6430-6435

  Blatner, Nichole R ^a   Bonertz, Andreas ^a,b   Beckhove, Philipp ^a,b   Cheon, Eric C ^a   Krantz, Seth B ^a   Strouch, Matthew ^a   Weitz, Juergen ^c   Koch, Moritz ^c   Halverson, Amy L ^a   Bentrem, David J ^a,d   Khazaie, Khashayarsha ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Interleukin 17; Interleukin 6

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6;

ADENOMATOUS POLYP; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL DAMAGE; CELL EXPANSION; CELL FUNCTION; CELL INTERACTION; CLINICAL ARTICLE; COCULTURE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DISEASE PREDISPOSITION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTE CULTURE; MAST CELL; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; POLYPOSIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANIMALS; COCULTURE TECHNIQUES; COLORECTAL NEOPLASMS; HUMANS; INTERLEUKINS; MAST CELLS; MICE; MICE, KNOCKOUT; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

MURINAE; MUS;

EID: 77950914422     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0913683107     Document Type: Article

References (35)

1. Khazaie K, Bonertz A, Beckhove P (2009) Current developments with peptide-based human tumor vaccines. Curr Opin Oncol 21:524-530.
2. Crivellato E, Nico B, Ribatti D (2008) Mast cells and tumour angiogenesis: New insight from experimental carcinogenesis. Cancer Lett 269:1-6.
3. Maltby S, Khazaie K, McNagny KM (2009) Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796:19-26.
4. Gounaris E, et al. (2007) Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 104:19977-19982.
5. Soucek L, et al. (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13:1211-1218. (Pubitemid 47530639)
6. de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411-423.
7. Lu LF, et al. (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997-1002.
8. Gounaris E, et al. (2009) T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res 69:5490-5497.
9. Gri G, et al. (2008) CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 29:771-781.
10. Kennedy Norton S, et al. (2008) IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol 180:2848-2854.
11. de Vries VC, et al. (2009) Mast cell degranulation breaks peripheral tolerance. Am J Transplant 9:2270-2280.
12. Piconese S, et al. (2009) Mast cells counteract regulatory T cell suppression through interleukin-6 and OX40/OX40L axis toward Th17 cell differentiation. Blood 114: 2639-2648.
13. Clarke SL, et al. (2006) CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 1:e129-135.
14. Ling KL, et al. (2007) Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 7:7-14.
15. Sinicrope FA, et al. (2009) Intraepithelial effector (CD3(+))/regulatory (FoxP3(+)) T-cell ratio predicts adverse outcome of human colon carcinoma. Gastroenterology 137: 1270-1279.
16. Salama P, et al. (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186-192.
17. Wang L, et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206:1457-1464.
18. Kryczek I, et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141-1149.
19. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114:357-359.
20. Bonertz A, et al. (2009) Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest .
21. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA (2009) Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 21:281-285.
22. Yang FC, et al. (2006) Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum Mol Genet 15:2421-2437.
23. Nonomura N, et al. (2007) Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer 97: 952-956. (Pubitemid 47519307)
24. Kirshenbaum AS, et al. (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/ leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27:677-682. (Pubitemid 36683255)
25. Murai M, et al. (2009) Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 10:1178-1184.
26. Contasta I, Berghella AM, Pellegrini P, Adorno D (2003) Passage from normal mucosa to adenoma and colon cancer: Alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 18:549-557. (Pubitemid 37082374)
27. Yang XO, et al. (2007) STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282:9358-9363.
28. Niemand C, et al. (2003) Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 170:3263-3272. (Pubitemid 36302204)
29. Devarajan E, Huang S (2009) STAT3 as a central regulator of tumor metastases. Curr Mol Med 9:626-633.
30. Goodman WA, et al. (2009) IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183:3170-3176.
31. Baltgalvis KA, et al. (2008) Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol 294:R393-R401.
32. Nadkarni S, Mauri C, Ehrenstein MR (2007) Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204:33-39. (Pubitemid 46148753)
33. Laurence A, et al. (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26:371-381. (Pubitemid 46413906)
34. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485-517.
35. Kashyap M, et al. (2008) Cutting edge: CD4 T cell-mast cell interactions alter IgE receptor expression and signaling. J Immunol 180:2039-2043.